Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 42 Issue 1, January 2021

Volume 42 Issue 1

Immunotherapy has achieved great outcome in clinic, and PD-1/PD-L1 immunotherapy is the most promising one. Due to the limitations of monoclonal antibodies, the discovery of small molecule drugs blocking PD-1/PD-L1 signaling has attracted great interest. In this issue, Wu et al summarized the advances in small molecule inhibitors targeting the PD-1/PD-L1.

Review Article

Article

Search

Quick links